7.75
-0.255(-3.19%)
Currency In USD
| Previous Close | 8.01 |
| Open | 8.06 |
| Day High | 8.42 |
| Day Low | 7.58 |
| 52-Week High | 36 |
| 52-Week Low | 3.44 |
| Volume | 51,541 |
| Average Volume | 151,970 |
| Market Cap | 56.82M |
| PE | -1.49 |
| EPS | -5.2 |
| Moving Average 50 Days | 8.11 |
| Moving Average 200 Days | 12.9 |
| Change | -0.26 |
If you invested $1000 in Biodesix, Inc. (BDSX) since IPO date, it would be worth $30.25 as of September 28, 2025 at a share price of $7.75. Whereas If you bought $1000 worth of Biodesix, Inc. (BDSX) shares 3 years ago, it would be worth $278.78 as of September 28, 2025 at a share price of $7.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biodesix Announces One-for-Twenty Reverse Stock Split
GlobeNewswire Inc.
Sep 11, 2025 12:00 PM GMT
LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
GlobeNewswire Inc.
Sep 05, 2025 10:00 AM GMT
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Mark
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
GlobeNewswire Inc.
Aug 19, 2025 1:47 PM GMT
Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated SequencerLOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized di